Dupilumab Therapy for EGIDs

Condition(s) studied

Investigational drug(s) / intervention(s)

Dupilumab - Standard Dose: Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.

subcutaneous injection: Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.

Study summary

This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.

Eligibility

Primary outcome measure(s)

• Endoscopic response rate — week12, week26, week52
  The ulcer reaches stage S (healed) or stage H (healing period), or the ulcer area has decreased by more than 50%.

Trial sites (1)